Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05281003 | Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)(HYPERION) | unknown | Phase 2 | 128 | Fudan UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05576909 | Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation | unknown | Phase 2 | 20 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jul 13, 2023 |
| clinicaltrials |
| NCT05879497 | 68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion | unknown | Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05879510 | 68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses | unknown | Phase 2 | 63 | Peking Union Medical College HospitalOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05941156 | Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05932173 | A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 60 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05940051 | Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 35 | Peng LiuOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05940064 | Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 30 | Peng LiuOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03695744 | Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma | unknown | Phase 2 | 27 | Singapore General HospitalOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT04267549 | Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer | unknown | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05631912 | TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL | unknown | Phase 1 / Phase 2 | 38 | Chinese PLA General HospitalOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05932264 | Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05928897 | Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab | unknown | Phase 2 | 30 | Xiangya Hospital of Central South UniversityOTHER | 0 | Jul 5, 2023 | clinicaltrials |
| NCT02679040 | Histological Response Rate After Mastectomy and Immediate Breast Reconstruction at the End of Neoadjuvant Chemotherapy and Radiotherapy(HIST-RIC) | unknown | Phase 2 | 101 | Institut Paoli-CalmettesOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT03925090 | Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05127590 | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | unknown | Phase 1 / Phase 2 | 50 | Ribon Therapeutics, Inc.INDUSTRY | 4 | Jul 3, 2023 | clinicaltrials |
| NCT05927779 | Study of TFX06 in Women With Advanced Breast Cancer. | unknown | Phase 1 / Phase 2 | 74 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05925413 | Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 41 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT03001570 | Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District(FAMOSO) | unknown | Phase 2 | 10 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04304352 | Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients(VEX) | unknown | Phase 2 | 162 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04671459 | TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine(TaRRGET) | unknown | Phase 2 | 40 | Prof. Franciszek Lukaszczyk Memorial Oncology CenterOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04797884 | Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma(ARTEMIS) | unknown | Phase 2 / Phase 3 | 166 | THERABIONIC INC.OTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05576532 | Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia | unknown | Phase 2 | 30 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT02760667 | Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer | unknown | Phase 2 | 20 | George Washington UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT04814615 | A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma | unknown | Phase 2 | 60 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05823987 | Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)(OPTIONS-05) | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05897268 | Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)(CASTLE-10) | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05919095 | A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer | unknown | Phase 2 | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02560298 | Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer(InterAACT) | unknown | Phase 2 | 91 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02786589 | Plasmodium Immunotherapy for Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | State Key Laboratory of Respiratory DiseaseOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03809780 | Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone(LENDER) | unknown | Phase 2 | 70 | Kosin University Gospel HospitalOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04619316 | Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition(ERRITI) | unknown | Phase 2 | 70 | University Hospital, EssenOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04803851 | Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 29 | Peking Union Medical College HospitalOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05751265 | Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer | unknown | Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05911425 | Combined Treatment of Treated Bile Duct Cancer(CHOL) | unknown | Phase 2 | 30 | Zhejiang Cancer HospitalOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05912205 | Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05913414 | Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 120 | Sun Yat-sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05913570 | Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer(MSI-H/dMMR) | unknown | Phase 2 | 22 | LiuYingOTHER_GOV | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05913661 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02396043 | Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03641456 | VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04072107 | EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)(EP-STAR) | unknown | Phase 2 | 110 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04221516 | Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 52 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05900765 | A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05908916 | Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 51 | Yonsei UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05910034 | Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC | unknown | Phase 2 | 132 | Fudan UniversityOTHER | 0 | Jun 18, 2023 | clinicaltrials |
| NCT05896046 | SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05902377 | 68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma | unknown | Phase 2 | 46 | Peking Union Medical College HospitalOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05903456 | Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma | unknown | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05904457 | A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer(BRISK) | unknown | Phase 2 | 32 | Asan Medical CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Jul 13, 2023source: clinicaltrials